Abstract
Secretin is the first hormone that has been discovered, inaugurating the era and the field of endocrinology. Despite the initial focus, the interest in its actions faded away over the decades. However, there is mounting evidence regarding the pleiotropic beneficial effects of secretin on whole-body homeostasis. In this review, we discuss the evidence from preclinical and clinical studies based on which secretin may have a role in the treatment of obesity.
Highlights
INTRODUCTIONObesity poses an additional risk for several diseases comprising cancer, neurodegeneration, cardiovascular disease (CVD), musculoskeletal disorders, and an increased vulnerability to infections [2,3,4,5,6]
We are currently facing a global epidemic of obesity [1]
Identifying pathways that lead to obesity for medical treatments of obesity is taking on a new urgency
Summary
Obesity poses an additional risk for several diseases comprising cancer, neurodegeneration, cardiovascular disease (CVD), musculoskeletal disorders, and an increased vulnerability to infections [2,3,4,5,6]. Of these CVD is the leading cause of death world-wide [7]. As recently demonstrated by Yoshino et al, the beneficial metabolic effects of BS can be ascribed solely to weight loss itself, rather than to any weight-lossindependent effects [8]. The intestines secrete several other hormones as well One such is secretin, which has recently gained back interest from the metabolic community. We describe the basic characteristics of secretin secretion and its effects on wholebody homeostasis, with special interest in its action as a satiation signal
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
